{'fraction_non_alphanumeric': 0.025297619047619048, 'fraction_numerical': 0.0, 'mean_word_length': 6.315217391304348, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacoeconomics and quality of life: The missing link

Terri Graves Davidson, Pharm D, FCCP, FASHP, is Clinical Associate, Hematology/Oncology, Department of Pharmaceutical Services, Emory University Hospital, Atlanta, Ga. Pharmacoeconomics and quality of life were major themes that resonated throughout the Fourth International Symposium on Oncology Pharmacy Practice. The following report, supplemented by information from the ISOPP IV Symposium, defines pharmacoeconomics research and describes the methods used to perform pharmacoeconomic analyses and quality of life studies. Results of original pharmacoeconomic studies performed in cancer patients are critiqued.